Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Intellia Therapeutics ( (NTLA) ).
On September 25, 2025, Intellia Therapeutics announced positive longer-term data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy. The trial showed deep, durable TTR reductions and favorable safety data, with most patients experiencing stability or improvement in clinical measures. The company is advancing its Phase 3 MAGNITUDE-2 trial, with completion of enrollment expected in the first half of 2026, and plans to submit a biologics license application by 2028.
The most recent analyst rating on (NTLA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics shows strong technical momentum and promising clinical trial progress, which are significant positives. However, the company’s financial performance is challenged by high R&D expenses and negative cash flows, typical for a biotech firm in development stages. The valuation reflects current unprofitability, and while the earnings call was positive, it highlighted some operational risks.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address unmet medical needs. The company aims to revolutionize medicine by leveraging gene editing technology to create novel, first-in-class medicines, particularly in the field of transthyretin amyloidosis.
Average Trading Volume: 5,092,015
Technical Sentiment Signal: Hold
Current Market Cap: $1.91B
For a thorough assessment of NTLA stock, go to TipRanks’ Stock Analysis page.